Fresenius Medical shares should be bought, says Bernstein Bernstein notes that Fresenius' (FMS) stock has sharply underperformed versus its competitor, DaVita (DVA), since May 2012. But the firm predicts that Fresenius' core U.S. business should outperform that of DaVita going forward. Bernstein adds that it finds Fresenius' business units aside from its U.S. dialysis clinics more attractive than DaVita's businesses other than its U.S. dialysis clinics.
News For FMS;DVA From The Last 14 Days
Check below for free stories on FMS;DVA the last two weeks.